These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 23748802)

  • 1. Association of breast cancer subtypes and body mass index.
    Petekkaya I; Sahin U; Gezgen G; Solak M; Yuce D; Dizdar O; Arslan C; Ayyildiz V; Altundag K
    Tumori; 2013; 99(2):129-33. PubMed ID: 23748802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association between body mass index and immunohistochemical subtypes in breast cancer.
    Sahin S; Erdem GU; Karatas F; Aytekin A; Sever AR; Ozisik Y; Altundag K
    Breast; 2017 Apr; 32():227-236. PubMed ID: 27756509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of established risk factors with breast cancer subtypes.
    McCarthy AM; Friebel-Klingner T; Ehsan S; He W; Welch M; Chen J; Kontos D; Domchek SM; Conant EF; Semine A; Hughes K; Bardia A; Lehman C; Armstrong K
    Cancer Med; 2021 Sep; 10(18):6456-6467. PubMed ID: 34464510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Body mass index at age 18 years and recent body mass index in relation to risk of breast cancer overall and ER/PR/HER2-defined subtypes in white women and African-American women: a pooled analysis.
    Ma H; Ursin G; Xu X; Lee E; Togawa K; Malone KE; Marchbanks PA; McDonald JA; Simon MS; Folger SG; Lu Y; Sullivan-Halley J; Deapen DM; Press MF; Bernstein L
    Breast Cancer Res; 2018 Jan; 20(1):5. PubMed ID: 29357906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Body mass index (BMI) and breast cancer: impact on tumor histopathologic features, cancer subtypes and recurrence rate in pre and postmenopausal women.
    Biglia N; Peano E; Sgandurra P; Moggio G; Pecchio S; Maggiorotto F; Sismondi P
    Gynecol Endocrinol; 2013 Mar; 29(3):263-7. PubMed ID: 23174088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic impact of obesity on molecular subtypes of breast cancer in premenopausal women.
    Turkoz FP; Solak M; Petekkaya I; Keskin O; Kertmen N; Sarici F; Arik Z; Babacan T; Ozisik Y; Altundag K
    J BUON; 2013; 18(2):335-41. PubMed ID: 23818343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Body size, physical activity, and breast cancer hormone receptor status: results from two case-control studies.
    Enger SM; Ross RK; Paganini-Hill A; Carpenter CL; Bernstein L
    Cancer Epidemiol Biomarkers Prev; 2000 Jul; 9(7):681-7. PubMed ID: 10919738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival.
    Ihemelandu CU; Leffall LD; Dewitty RL; Naab TJ; Mezghebe HM; Makambi KH; Adams-Campbell L; Frederick WA
    J Surg Res; 2007 Nov; 143(1):109-18. PubMed ID: 17950079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Height, body mass index (BMI), BMI change, and the risk of estrogen receptor-positive, HER2-positive, and triple-negative breast cancer among women ages 20 to 44 years.
    Kawai M; Malone KE; Tang MT; Li CI
    Cancer; 2014 May; 120(10):1548-56. PubMed ID: 24500704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Body mass index, age at breast cancer diagnosis, and breast cancer subtype: a cross-sectional study.
    Brouckaert O; Van Asten K; Laenen A; Soubry A; Smeets A; Nevelstreen I; Vergote I; Wildiers H; Paridaens R; Van Limbergen E; Weltens C; Moerman P; Floris G; Neven P;
    Breast Cancer Res Treat; 2018 Feb; 168(1):189-196. PubMed ID: 29159760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obesity, body fat distribution, and risk of breast cancer subtypes in African American women participating in the AMBER Consortium.
    Bandera EV; Chandran U; Hong CC; Troester MA; Bethea TN; Adams-Campbell LL; Haiman CA; Park SY; Olshan AF; Ambrosone CB; Palmer JR; Rosenberg L
    Breast Cancer Res Treat; 2015 Apr; 150(3):655-66. PubMed ID: 25809092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831.
    Crozier JA; Moreno-Aspitia A; Ballman KV; Dueck AC; Pockaj BA; Perez EA
    Cancer; 2013 Jul; 119(13):2447-54. PubMed ID: 23585192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anthropometric factors and risk of molecular breast cancer subtypes among postmenopausal Norwegian women.
    Horn J; Alsaker MD; Opdahl S; Engstrøm MJ; Tretli S; Haugen OA; Bofin AM; Vatten LJ; Asvold BO
    Int J Cancer; 2014 Dec; 135(11):2678-86. PubMed ID: 24752603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hip circumference is associated with the risk of premenopausal ER-/PR- breast cancer.
    Fagherazzi G; Chabbert-Buffet N; Fabre A; Guillas G; Boutron-Ruault MC; Mesrine S; Clavel-Chapelon F
    Int J Obes (Lond); 2012 Mar; 36(3):431-9. PubMed ID: 21427693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer.
    Chen L; Cook LS; Tang MT; Porter PL; Hill DA; Wiggins CL; Li CI
    Breast Cancer Res Treat; 2016 Jun; 157(3):545-54. PubMed ID: 27220749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Body weight and risk of molecular breast cancer subtypes among postmenopausal Mediterranean women.
    Crispo A; Montella M; Buono G; Grimaldi M; D'Aiuto M; Capasso I; Esposito E; Amore A; Nocerino F; Augustin LS; Giudice A; Di Bonito M; Giuliano M; Forestieri V; De Laurentiis M; Rinaldo M; Ciliberto G; De Placido S; Arpino G
    Curr Res Transl Med; 2016; 64(1):15-20. PubMed ID: 27140595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The diverse distribution of risk factors between breast cancer subtypes of ER, PR and HER2: a 10-year retrospective multi-center study in China.
    Song Q; Huang R; Li J; Fan J; Zheng S; Zhang B; Yang H; Tang Z; He J; Xie X; Li H; Li J; Qiao Y
    PLoS One; 2013; 8(8):e72175. PubMed ID: 23977244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
    Parise CA; Bauer KR; Brown MM; Caggiano V
    Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Body mass index, mammographic density, and breast cancer risk by estrogen receptor subtype.
    Shieh Y; Scott CG; Jensen MR; Norman AD; Bertrand KA; Pankratz VS; Brandt KR; Visscher DW; Shepherd JA; Tamimi RM; Vachon CM; Kerlikowske K
    Breast Cancer Res; 2019 Apr; 21(1):48. PubMed ID: 30944014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Basal-like immunophenotype markers and prognosis in early breast cancer.
    Cassol L; Silveira Graudenz M; Zelmanowicz A; Cancela A; Werutsky G; Rovere RK; Garicochea B
    Tumori; 2010; 96(6):966-70. PubMed ID: 21388060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.